Betterlife Pharma Inc. (BETRF)

[NetworkNewsWire]

PVOTF is “One to Watch”

- Transdermal cannabis-based therapy promises greater absorption, less side effects
- Global medical marijuana market projected to reach $55.8 billion U.S. by 2025
- Novel CBD delivery method targets array of unmet healthcare needs

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

For more information, visit the company’s website at www.PivotPharma.com

[JohnCM]

Pivot Files Three New Provisional Patents for the Delivery of Cannabinoids

News file February 1, 2018

Vancouver, British Columbia--(Newsfile Corp. - February 1, 2018) - Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) ("Pivot" or the "Company"), is pleased to announce that it has filed three provisional patents with the United States Patent and Trademark Office ("USPTO") related to the delivery of cannabinoid-based products. The applications cover the following areas:

1. Transdermal nanotechnology delivery system of cannabis using patches and creams;
2. Mucus topical cannabis delivery system through buccal, nasal, vaginal and anal areas of entry using a gel, suppository or mouthwash;
3. Inhalation delivery system of cannabis for topical or systemic.

Pivot continues to build a world-class Intellectual Property ("IP") portfolio of pharmaceutical-grade formulations as the Company prepares to commercialize an industry leading pipeline of cannabinoid-based consumer healthcare products. In addition to the latest filing of provisional patents described above, Pivot has previously secured worldwide rights to topical, oral, transdermal and food and beverage patented technologies. Pivot's scientific advisors, Dr. Leonid Lurya and Dr. Joseph Borovsky, are the patent inventors and will facilitate the scale-up of products from these technologies.

Dr. Patrick Frankham, Pivot's CEO states "Pivot's key competitive advantages include cannabis formulation and delivery technologies, scientific and regulatory expertise, product sales and distribution experience, and our ability to work with best-in-class global partners. The patent filings announced today demonstrate that our research and development program continues to generate valuable IP for our robust pipeline of health and wellness products. We continue to create shareholder value by building a sustainable, long-term company that is well positioned in the fast-changing cannabis industry."

The international market for cannabis is projected to hit $31.4 billion by 2021, according to a new report from the Brightfield Group, a cannabis market research firm. Currently, the global market is estimated to be worth $7.7 billion and will see a compound annual growth rate of 60 percent as other countries liberalize their marijuana laws.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot's wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS' initial product development candidates will include topical treatments for women's sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Pivot Continues To Build Technology Portfolio

Globe News wire January 17, 2018

VANCOUVER, British Columbia, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (PVOTF) (“Pivot” or the “Company”), and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), are pleased to provide its shareholders with a Corporate Update.

Since Pivot’s entry into the cannabis industry, we have accumulated the following four patented or proprietary technologies to deliver cannabinoids into the human body that avoid exposure to carcinogens from smoking:

1. BiPhasix Transdermal Delivery System (semi-solid topical cream);
2. Thrudermic Nanoparticulate Transdermal Delivery System (gel or patch);
3. SolMic Micelle Water Soluble Oral Delivery System (oral dropper bottle); and
4. RTIC Cannabis Oil-To-Powder System (powder for infusion into food and beverages).

Each of Pivot’s technologies will allow the Company to develop and monetize dozens of products in various strengths and concentrations (with or without THC) addressing many unmet medical needs and favouring a healthy lifestyle. The pipeline that Pivot is developing will enable it to deliver meaningful doses (e.g. better bioavailability) of cannabinoids, unlike current products marketed today.

Pivot’s products will have a shelf-life that will enable them to remain fresh and stable and have clinical data to support efficacy and safety claims in order to be used to manage a particular health condition. As well, each of our technologies allow for the smell and taste of cannabinoids to be greatly improved. Lastly, our products will be manufactured in a world class facility of pharmaceutical grade using only the purest of cannabis extracts.

Pivot will develop its products in markets where cannabinoids can be sourced and formulated without restriction. The Company recently announced that it will develop its cutting-edge cannabis products in Israel and in Germany, working with world class scientists to bring our impressive pipeline of products to market in 2018.

Dr. Patrick Frankham, Pivot’s CEO, states that “we are proud of the progress that the Company has made during the past few months. As the market prepares for legalization, it is Pivot’s belief that only products that are doseable and have high bio-availability will differentiate themselves from those delivered using simple tropical or vegetable based oils. Our intellectual property portfolio easily distinguishes us from our competitors.”
About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. RTIC ready to infuse cannabis containing foods and beverages will allow patients and consumers to include cannabis into their daily lifestyle without the side effects of high carbohydrate or poor tasting presentations. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com.

[georgie18]

PVOTF...$1.76...Chart...News...Overbought Retrace...looking for 20ma bounce...

https://www.otcmarkets.com/stock/PVOTF/news/Pivot-Continues-To-Build-Technology-Portfolio?id=180617&b=y

Market Value1 $144,977,488 a/o Jan 16, 2018
Authorized Shares Unlimited a/o Jan 16, 2018
Outstanding Shares 82,373,573 a/o Jan 16, 2018
Restricted 36,989,060 a/o Jan 16, 2018
Unrestricted 45,384,513 a/o Jan 16, 2018
Held at DTC Not Available
Float 54,698,872 a/o Dec 12, 2017
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
National Issuer Services Ltd.

[atomicnumber31]

https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aPVOT-2552387&symbol=PVOT®ion=C

[atomicnumber31]

www.cannabisfn.com/pivot-pharma-wraps-successful-2017/

The North American cannabis industry reached $6.7 billion in 2016, according to ArcView Research, which represented a healthy 30% growth rate over the prior year. Over the next three years, the analyst firm expects the industry to grow at a 25% compound annual growth rate to reach $20.2 billion in sales. One company, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF), successfully completed an about-face in 2017 to focus exclusively on the explosive sector. In this article, we will review the company’s achievements and how its business model aligns with trends in the industry.
New Focus on Cannabis
Pivot Pharmaceuticals first announcement related to cannabis came on September 12, 2017. The company acquired worldwide rights and a patent for the proprietary BiPhasix™ Transdermal Drug Delivery technology, for the development of cannabis-related products. The technology has been shown to significantly enhance the bioavailability of drugs by transporting them effectively through the skin, and the drugs delivered in this manner can target peripheral areas of the body to deliver a payload through the skin without damaging the organ from repeated application.
The acquisition was intended to address cannabinoid delivery which is an overarching problem throughout the industry. Smoking is not necessarily a preferred delivery mechanism due mostly to side effects and health concerns, and ingestion is ineffective due to metabolic effects of the liver as well as inherent problems with the absorption of cannabinoids due to insolubility in water. So Pivot Pharma’s first move was to acquire a proven technology and focus it on cannabis. But the company was by no means done.
Pivot announced two weeks later the acquisition of worldwide rights to Solmic Research GmbH’s Solmic Solubilisation Technology. This is an oral delivery technology that makes cannabinoids water-soluble and protects them from degradation due to stomach acids and enzymes. The technology masks unpleasant odour and taste and improves stability of the mixture. Pivot is advancing several Natural Health Products as a result of this technology, including products intended for opioid addicts and cancer patients.
A few weeks later, in early November, Pivot entered into a binding agreement to acquire a third delivery technology, Thrudermic’s Transdermal Nanotechnology. This new technology allows Pivot to control and prolong the release of cannabinoid actives while maintaining high concentrations of the drug throughout the application period. Unlike BiPhasix™, the Thrudermic technology allows for more sophisticated systemic exposure from fast uptake to slow release.
Taken together, the three delivery technologies provide a wide array of options for development and commercialization of cannabinoid-based nutraceuticals and medicines. While many companies are focused on the production and sale of cannabis flower products, there is an increasing demand for more specific and refined products utilizing extracts from the cannabis plant.
Positioning for a Big Year
With some innovative delivery technologies in place, Pivot Pharma entered into another binding agreement, this time for the acquisition of ERS Holdings, LLC. ERS has a patented technology called Ready to Infuse Cannabis (RTIC) that changes cannabis oil extracts into a tasteless powder suitable for infusion into food and beverage products. Cannabis oils suffer from the above-mentioned bioavailability issues, but also have a notorious taste problem. The RTIC technology solves both issues, and opens up a whole world of consumer product possibilities for Pivot Pharmaceuticals.
In a final move before the end of the year, the company entered into a binding agreement to establish a California-based business to accelerate the commercialization of the newly-acquired RTIC powders. With California poised to fully legalize cannabis on Jan. 1, 2018, thereby becoming the world’s largest legal cannabis market, Pivot is looking to quickly capitalize on the innovative technology.
Looking Ahead
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) just recently started trading on the Canadian Securities Exchange, opening up the company’s stock to a whole new market of cannabis-savvy investors. Additionally, the company announced a 45-day standstill agreement that will end on February 6, 2018. In the interim, Pivot hopes to finalize a partnership with a “…best-in-class partner to monetize our patented technologies…” The agreement means that Pivot will not enter into or negotiate any other partnerships within the 45-day period. Read into this what you will, but with Canada and California both legalizing adult use of cannabis in 2018, the year ahead should be full of interesting developments for Pivot Pharmaceuticals.
For more information, visit the company’s website at www.pivotpharma.com.

[atomicnumber31]

Pivot signs standstill deal with potential partner

2017-12-27 06:27 ET - News Release

Mr. Patrick Frankham reports

PIVOT ENTERS INTO STANDSTILL AGREEMENT

Pivot Pharmaceuticals Inc. has entered into a 45-day standstill period with a Toronto Stock Exchange-listed company in order to explore a business opportunity of mutual interest and benefit, that may result in a co-research and development program, a product launch and/or commercialization agreement, or some other form of potential partnership.

The standstill period will end on Feb. 6, 2018. During this time Pivot will not, directly or indirectly, conduct or enter negotiations or engage in any other discussions or communications with any third party regarding a potential transaction, any sale of all or substantially all of the assets of Pivot, or any merger, amalgamation, plan of arrangement or other business combination involving Pivot.

Dr. Patrick Frankham, Pivot's chief executive officer, stated that: "The Pivot team has been working tirelessly to secure a best-in-class partner to monetize our patented technologies and to bring our impressive pipeline of products to market in preparation for the legalization of cannabis in Canada and areas of the U.S. and European Union. During the past few months we have garnered interest from established companies in the nutraceutical and cannabis industries. Pivot's management is committed to exploring all potential avenues to consummate a transaction with the company that we have a standstill agreement with as they share our vision of developing, manufacturing and commercializing premium science-based cannabis products to serve the health needs of consumers. On behalf of the board of directors of Pivot, I would like thank our shareholders for their continued support and wish them a healthy and prosperous 2018."

[atomicnumber31]

HUGE NEWS....

....and a signal to others wishing to get a piece to "GET IN LINE".....

Awesome

[atomicnumber31]

Wow what a day...!!

[atomicnumber31]

More TO COME....THIS IS JUST THE START....

[atomicnumber31]

NEWS !!!!

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2017) - Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) ("Pivot" or the "Company"), and its wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), are pleased to announce that Pivot has signed a binding letter of intent to establish a California-based entity ("PGS-California") in order to accelerate the monetization of the Ready To Infuse Cannabis ("RTIC") technology as previously announced on December 20, 2017. Pivot plans to build manufacturing facilities in legal cannabis markets throughout North America and Europe, obtain the necessary licensures, and launch products using RTIC technology which transforms cannabis oil into powder for infusion. The letter of intent is subject to customary conditions including regulatory approval, the negotiation of a definitive agreement and satisfactory completion of due diligence.

Pivot seeks to gain market share in the food and beverage segment of the cannabis industry in legal markets in the near term through in-house brand development and by providing co-packing services for other edible brands through strategic partnerships. Co-packing services are an underserved, high-demand segment of the cannabis industry on the B2B side and will help further the awareness and visibility of the "Made with Instant THC" & "Made with Instant CBD" brands.

Pivot will appoint Ross Franklin and Patrick Rolfes to executive leadership roles within PGS-California to help execute its business strategy of conducting research, development and commercialization of cannabinoid-based products. Mr. Rolfes states that, "Pat and I look forward to working with Pivot to monetize the RTIC patents. Our facilities will be able to produce a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottle beverages."

Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals stated that, "Pivot continues to execute on its business strategy to upscale cannabis oils into premium healthcare and nutritional products. The California cannabis market is estimated to be worth $7B annually making it an attractive territory for Pivot's pipeline of products and technologies. We are also delighted to announce that Ross Franklin will join our Scientific Advisory Board. His extensive cannabis product development and commercial expertise will be a great asset to Pivot as we enter the US market."

Following the passing of Adult Use of Marijuana Act (Prop. 64), cannabis will be legal in California beginning January 1, 2018. California's main regulatory agencies are the Bureau of Cannabis Control (BCC), Department of Food and Agriculture, Department of Public Health and Cannabis Regulatory Authority (CRA). PGS-California will apply for all necessary licenses with the appropriate agencies.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot's wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS' initial product development candidates will include topical treatments for women's sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com.

[atomicnumber31]

I think you are going to do very well here...

[Perk71]

I forgot a put a sell in yesterday and they bought it right before the halt.

[atomicnumber31]

HALTED !!!!!

[atomicnumber31]

Awesome Perk !!!...fireworks coming I expect...

[atomicnumber31]

LOVE THIS PART

Invented by Ross Franklin and Ed Rosenthal, the invention "relates generally to methods and compositions of matter for enabling concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages or food by combining cannabis oil with a starch powder or starch-derived powder. Embodiments also relate to a variety of culinary uses for the stabilized, emulsified, flavorless concentrated cannabis oil powder."

Mr. Franklin, ERS' CEO, said that "after being courted by some of Canada's largest cannabis companies, we selected the Pivot team to help monetize our patent. Their management team has extensive pharmaceutical and nutraceutical industry experience and an impressive track record of bringing products to market. In addition to the food and beverage markets, we also look forward to integrating "RTIC" into Pivot's current topical, oral and nanoparticulate pipeline."

[Perk71]

Got in yesterday...

[atomicnumber31]

LATEST NEWS

Pivot Pharmaceuticals to acquire ERS Holdings


2017-12-20 06:41 ET - News Release



Dr. Patrick Frankham reports

PIVOT PHARMA SIGNS BINDING LETTER OF INTENT TO ACQUIRE CANNABIS OIL INFUSION TECHNOLOGY FOR USE IN FOOD AND BEVERAGE PRODUCTS

Pivot Pharmaceuticals Inc. has signed a binding letter of intent to acquire ERS Holdings LLC, a privately held California company. ERS has developed a patented technology called "RTIC" - Ready To Infuse Cannabis ("the Patent") and has also filed several continuation patents relating to the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions and bottled beverages.

In exchange for 100% of ERS (Patent Portfolio and Trademarks for "Instant THC™" and "Instant CBD™"), Pivot will pay ERS $1,000,000 USD and 5,000,000 Common Shares ("The Shares") of Pivot Pharmaceuticals Inc. The Shares will be subject to a six (6) month restriction with the first 25% of the total number of Shares to be released six (6) months following the closing date, with 25% to be released every quarter thereafter. Completion of the acquisition is subject to regulatory approval and standard closing conditions.

A recent report by Deloitte suggests that "on sales of recreational marijuana alone, the Canadian marketplace could be as much as $5B per year to start — a number on par with the Canadian spirit market (whiskey, vodka, rum, etc.). At the upper threshold, which takes into account the people who are "likely to consume," marijuana sales alone could be as high as $8.7B, similar to sales generated by wine."

Current cannabis product formulations are either poorly absorbed topicals and orals or inhaled and smoked carcinogens. Health-conscious adults who seek the therapeutic benefits of cannabis without the negative health effects represent a large, untapped demographic. This demographic is also inundated with edible product choices that are high in sugar, such as candy or confectionary. Health-seeking consumers who use cannabis daily represent a large market opportunity for Pivot. The acquisition of ERS allows Pivot to add to its growing pipeline of cannabis-based products.

Invented by Ross Franklin and Ed Rosenthal, the invention "relates generally to methods and compositions of matter for enabling concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages or food by combining cannabis oil with a starch powder or starch-derived powder. Embodiments also relate to a variety of culinary uses for the stabilized, emulsified, flavorless concentrated cannabis oil powder."

Mr. Franklin, ERS' CEO, said that "after being courted by some of Canada's largest cannabis companies, we selected the Pivot team to help monetize our patent. Their management team has extensive pharmaceutical and nutraceutical industry experience and an impressive track record of bringing products to market. In addition to the food and beverage markets, we also look forward to integrating "RTIC" into Pivot's current topical, oral and nanoparticulate pipeline."

Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated that "Pivot believes that the anticipated changes in cannabis regulation in Canada and California will provide an opportunity to launch multiple products into the healthcare and recreational markets in 2018. We are delighted that Ross Franklin and Pat Rolfes from ERS have chosen Pivot to help transform their patents and processes into therapeutic consumer goods. Pivot is in ongoing discussions with several Canadian Licensed Producers and Licensed Dealers in order to accelerate commercialization of our large pipeline of technology-driven products. If a suitable joint venture partner is not identified by January 2018, Pivot will seek a Licensed Dealer designation from Health Canada and commence construction of its own production facility. As a result, Pivot has engaged CBRE, the world's largest commercial real estate firm, to help facilitate the site selection process."

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot's wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS' initial product development candidates will include topical treatments for women's sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

[atomicnumber31]

Dec 21 article

Pivot Pharma Moves to Acquire Cannabis Infusion Technology



The cannabis industry may be experiencing significant growth, but it’s still much smaller than the global food and beverage industry, which is valued at nearly $100 billion. With the possibility of cannabis cannibalizing the sale of certain adult beverage markets, there has been a growing interest in partnerships between beer, wine, and spirits companies and cannabis companies to eventually develop cannabis-infused products for consumers.



In this article, we will take a look at Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) and why it’s well positioned to capitalize on the growing demand for cannabis-infused products, which has become an area of increasing interest for food and beverage companies.



Cannabis Infused Products



Canada’s cannabis industry is projected to reach $22.6 billion in size over the coming years, according to Deloitte, driven by the legalization of recreational marijuana. While dried marijuana has been the primary area of focus, cannabis oils and extracts are the fastest growing subset of the burgeoning industry. The legalization of these products has expanded the market to non-smoking consumers and further legislation surrounding edibles could do much more.



The interest in cannabis-infused edibles is underscored by Constellation Brands Inc.’s (NYSE: STZ) recent acquisition of a minority stake in Canopy Growth Corp. (TSX: WEED), a leading licensed producer of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). Constellation Brands is a leading international producer and marketer of beer, wine, and spirits with operations around the world.



Cowen & Co. has found evidence that the craft beer markets in Colorado, Oregon, and Washington State have been impacted by the legalization of recreational marijuana. The volume of craft beer sold in these states fell 2% in 2016 despite a 0.5% increase throughout the rest of the United States. In Denver, these volumes were down over 5% in 2016. The cannabis industry has also eclipsed the craft beer industry in size, making it an appealing diversification.



Pivot Pharma Enters the Space



Pivot Pharma recently announced that it has signed a binding letter of intent to acquire ERS Holdings LLC, a privately-held California company that has developed a patented Ready to Infuse Cannabis technology (“RTIC”) that enables the transformation of cannabis oil into powder and designed to be infuse into a variety of food and beverages. In particular, thetechnology converts cannabis oil into tasteless powders that can be infused into products like K-Cups, stick packs, baked mixes, shots, shakes, topicals and bottled beverages.



“Pivot believes that the anticipated changes in cannabis regulations in Canada and California will provide an opportunity to launch multiple products into the healthcare and recreational markets in 2018,” said Pivot Pharma CEO Dr. Patrick Frankham. “We are delighted that Ross Franklin and Pat Rolfesfrom ERS have chosen Pivot to help transform their patents and processes into therapeutic customer goods.”



Pivot previously acquired three other technologies that address the problems inherent in the delivery of cannabinoids. These include an oral solution (Solmic Solubilisation), a transdermal approach (BiPhasix™ Transdermal Drug Delivery Platform), and nanotechnology for topical applications (Thrudermic). The newly acquired powder technology extends the company’s capacities while also complementing its existing assets, as the powder could potentially be integrated into Pivot’s other delivery mechanisms.



Pivot Pharma is already engaged in discussions with several Canadian licensed producers and licensed dealers to accelerate the commercialization of its large pipeline of technology-driven products. If it doesn’t find a joint venture, management plans to seek a Licensed Dealer designation from Health Canada and begin building its own production facility. A Licensed Dealer can house, research, test, develop and sell products associated with cannabis and other drugs in ways that companies holding Licensed Producer permits cannot.



Looking Ahead



The global food and beverage market is worth nearly $100 billion, according to Statista, and continues to experience tremendous growth. The cannabis industry could have an outsized impact on certain segments of the adult beverage market, such as the adult recreational and functional foods sectors, given the similarity in demographics. This has led some companies to acquire ownership stakes in cannabis companies, but others could pursue joint ventures or licensing agreements with cannabis firms.



Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) (CSE: PVOT) is well-positioned to capitalize on these dynamics following its letter of intent to acquire ERS Holdings LLC. In combination with its plans to partner with or acquire a Licensed Dealer, the company will be capable of producing a variety of cannabis-infused products targeting the massive food and beverage industry. This could create opportunities for joint ventures or other favorable events down the road.

Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.pvot&postid=27203377#jqE1Hj0TKhD2GHvP.99

[atomicnumber31]

In at a $1 big things coming I hear.

[IPO$]

...JB ref

[dingleheimer]

[url][/url][tag]https://pivotpharma.com/[/tag]

major moves made in past year and more to come from the looks of it

[dingleheimer]

this ones ready to go boom!

[cotf]

PVOTF 0% 1.07, 1.06(x1) X 1.07(x1), no one's whacked the 1.06 bid yet - good sign

[cotf]

PVOTF 7% 1.07, .5423(x1) X 1.07(x1), 1.05 got bidwacked...

[cotf]

PVOTF 2% 1.02, 1.05(x2) X 1.07(x1)

[cotf]

PVOTF 2% 1.02, 1.02 X 1.05

[cotf]

PVOTF 3% 1.00, .67 X 1.00 - BOOOOOOOOOOOOOOOMMMMM!!!!

[cotf]

PVOTF 0% .97, .5221 X .99, .97'S GONE, even with the 1,500 .95 bidwack

[cotf]

PVOTF 2.11% .97, .91 X .97, .97 paint. Gonna throw a few hundred share sell @ ASK & test it

[cotf]

PVOTF -.053% .945, .91 X .97, ASK uptick now, looking at dollar(s) today!

[cotf]

PVOTF -.053% .945, .91 X .95, 17,100 SHARES TOOK OUT .94 & .945, .95 UP & NEXT LEG.............

[cotf]

PVOTF .92, .92 X .94 last few days they keep dropping the ASK a few cents lower after its hit to make it appear the stocks dropping I guess. Yesterday the BID was dropped way down to .50 - .60. Today the BID was .60 until the .92 ASK got taken out.

[Estrella]

$PVOTF @ .95!

[cotf]

08/12/15 PVOTF News:Appoints Dr. Pravin Chaturvedi, PhD to Chair Scientific Advisory Board [Market News Publishing (US)]

PIVOT PHARMACEUTICALS INC

PIVOT PHARMACEUTICALS INC ("PVOTF-0") - Appoints Dr. Pravin Chaturvedi, PhD to Chair Scientific Advisory - Board

Pivot Pharmaceuticals Inc. ("Pivot" or the "Company"), a biotechnology company engaged in the development and repositioning of existing drugs with a focus on unmet medical needs in women's health, is pleased to announce the appointment of Dr. Pravin Chaturvedi, PhD, as Chairman of its Scientific Advisory Board (SAB).

Dr. Chaturvedi is the Founder and Chairman of IndUS Pharmaceuticals and co-founder of Oceanyx Pharmaceuticals, serving as the Chief Executive Officer of both organizations. He is the former Chief Scientific Officer of Napo Pharmaceuticals. In addition, he is the Chair of the Research Advisory Council for the Health Sciences Center of West Virginia University and is an adjunct faculty member at Georgetown Medical School. Prior to IndUS Pharmaceuticals, he served as the President and Chief Executive Officer of Scion Pharmaceuticals.

During his 25+ year career in the pharmaceutical industry, Dr. Chaturvedi has participated in the discovery and/or development activities for many new chemical entities (NCEs), culminating in the successful development and commercialization of several new drugs that are currently marketed by various companies. Prior to Scion, he was the Head of Lead Evaluation at Vertex Pharmaceuticals, and previously in the pre-clinical group at Alkermes. He started his R & D career with the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer). Dr. Chaturvedi holds a PhD in Pharmaceutical Sciences from West Virginia University and a Bachelor of Science in Pharmacy from the University of Bombay.

"I am pleased and excited to be joining the Scientific Advisory Board of Pivot Pharmaceuticals," said Dr. Chaturvedi. "Over my long career in the pharmaceutical industry I have seen dramatic changes in healthcare and the introduction of several innovative and transformative drugs that have improved patient lives. Pivot's focus on women's health represents an important area of significant underserved medical need. I am pleased to be able to participate and collaborate with the very experienced leadership team of Pivot Pharmaceuticals as it starts to develop novel therapeutic agents."

Pivot's Chairman, Dr. Ahmad Doroudian said, "We are extremely thrilled to welcome Dr. Chaturvedi to Chair our Scientific Advisory Board. He is experienced in founding, managing, financing and directing startup pharmaceutical companies. The wealth of knowledge he brings with him relating to the discovery and development of novel drugs and managing their development for global commercialization will be of great assistance to Pivot's management team as we strive to become a leader in women's health."

The SAB's mission is to assist Pivot's management team in maximizing the value of the company's product pipeline, primarily by advising on scientific and research focus, clinical studies, safety and regulatory issues, commercialization opportunities, and assessing potential re-profiling candidates. Pivot's CEO, Dr. BJ Bormann said, "I can't think of a more experienced advisor for Pivot to be able to work with. We are all looking forward to progressing the Pivot programs towards the women that need these treatments."

About Pivot Pharmaceuticals Inc.

Pivot is an early stage biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceutical products, with a strategic emphasis on the innovation of new therapeutic uses for existing drugs to treat unmet conditions related to women's health. Pivot has identified ideal candidates for the treatment of Dysmenorrhea, lower urinary tract symptoms (LUTS), and menopausal symptoms (hot flushes).

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot's products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Pivot Pharmaceuticals Inc. BJ Bormann Chief Executive Officer

OTCBB closing price for PVOTF-0 Date: 2015/08/11 Closing Price: 0.46

____________________________________________________________
(c)2015 Market News Publishing Inc. All rights reserved.
Toronto:[phone] Vancouver:[phone] Fax:[phone]

© (c) 2015 Market News Publishing Inc.

[cotf]

PVOTF .53 on Monday, heavy volume week, may be more news/updates coming soon

[explorer99]

All I gotta say is WTF?

Love the action on low volume. Once they start putting out some PR this thing is going to fly!
Anyone have any insight?

[cotf]

PVOTF 8.43% .90, .845 X .94

[cotf]

PVOTF 6% .88, .83 X .89

[cotf]

PVOTF 19.40% .80, .75 X .83

[cotf]

PVOTF 13.43% .76, .75 X .80 $$$ flowing in.........

[cotf]

PVOTF 7.46% .72, .72 X .75, dollar(s) coming soon

[explorer99]

Well this is a nice surprise!

Very rarely do one of my dive picks become "unstuck"!
Thank you Pivot People!!!!

So, what is actually going on? I checked out the website (sharp!) and see that the management team is pretty impressive. They must have something up their sleeve......

Does anyone have any comparable companies that I can put on my watch list to see what kind of value they are commanding?

Enjoy the ride. Wish I had the funds and the guts to pick some more of this up way sooner.

[cotf]

PVOTF 4.69% .67, .67 X .70, new day, new high

[cotf]

PVOTF - technically it didn't go from there because the 1:100 r/s split with NEUKF, you'd have to adjust for that (.01 pre split to .10 post split). Still a heck of a ride, which appears to be picking up here now, glad I held my NEUKF shares!!!

[Estrella]

$PVOTF @ .64!
What a ride, from .0018-.64, priceless!!

[cotf]

PVOTF 19% .64, .62(x1) X .67(x1)

[stocktrademan]

$PVOTF recent news/filings

bullish

## source: finance.yahoo.com

Wed, 12 Aug 2015 13:00:00 GMT ~ Pivot Appoints Dr. Pravin Chaturvedi, PhD to Chair Scientific Advisory Board

[GlobeNewswire] - Vancouver, British Columbia -- Pivot Pharmaceuticals Inc. (OTCPK: PVOTF) ("Pivot" or the "Company"), a biotechnology company engaged in the development and repositioning of existing ...

read full: http://finance.yahoo.com/news/pivot-appoints-dr-pravin-chaturvedi-130000420.html
*********************************************************

Sat, 20 Jun 2015 17:04:07 GMT ~ PIVOT PHARMACEUTICALS INC. Financials


read full: http://finance.yahoo.com/q/is?s=pvotf
*********************************************************

$PVOTF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$PVOTF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PVOTF/company-info
Ticker: $PVOTF
OTC Market Place: OTC Pink Current
CIK code: 0001464165
Company name: Pivot Pharmaceuticals Inc.
Company website: http://www.pivotpharma.com
Incorporated In: British Columbia, Canada

Business Description: Pivot Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

$PVOTF share structure

## source: otcmarkets.com

Market Value: $42,138,615 a/o Aug 24, 2015
Shares Outstanding: 78,763,767 a/o Jun 17, 2015
Float: Not Available
Authorized Shares: Unlimited a/o Apr 29, 2015
Par Value: Not Available

$PVOTF extra dd links

Company name: Pivot Pharmaceuticals Inc.
Company website: http://www.pivotpharma.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PVOTF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PVOTF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PVOTF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PVOTF/news - http://finance.yahoo.com/q/h?s=PVOTF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PVOTF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PVOTF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PVOTF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PVOTF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Pivot+Pharmaceuticals+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Pivot+Pharmaceuticals+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Pivot+Pharmaceuticals+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.pivotpharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.pivotpharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.pivotpharma.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PVOTF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001464165&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PVOTF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PVOTF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PVOTF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PVOTF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PVOTF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PVOTF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PVOTF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PVOTF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PVOTF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PVOTF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PVOTF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PVOTF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PVOTF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PVOTF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PVOTF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PVOTF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PVOTF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PVOTF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PVOTF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PVOTF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PVOTF



$PVOTF DD Notes ~ http://www.ddnotesmaker.com/PVOTF

[cotf]

PVOTF 14% .61, .5551(x1) X .61(x1)

[cotf]

PVOTF 6.5% .57, .5501(x1) X .60(x1)- NITE dancing back & forth on the BID here from .40 - .58), about to test .60

[cotf]

PVOTF - .53, .53(x2) X .535(x1) daily hits on ASK, this thing is seemingly being accumulated, very little sells